BIO 2024 | Schedule 1-on-1 Meetings with us!

Biocytogen’s antibody business development and licensing (BDL) team is excited to host 1-on-1 meetings at Bio International Convention 2024, taking place from June 3-6, 2024…

Read more
GV Safety Assessment Platform (GVSAP) and Biocytogen Forge Strategic Collaboration to Accelerate Biopharmaceutical Innovation

Source: https://www.businesswireindia.com/gv-safety-assessment-platform-gvsap-and-biocytogen-forge-strategic-collaboration-to-accelerate-biopharmaceutical-innovation-90079.html Hyderabad, Telangana, India – May 17, 2024 – GV Safety Assessment Platform (GVSAP), a leading integrated R&D enabler offering comprehensive preclinical research solutions,…

Read more
Biocytogen Enters into Evaluation and Potential Licensing Agreement with BioCopy for TCR-mimic Antibodies

Beijing, China, May 6, 2024 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based…

Read more
May 2024 Newsletter

New Animal Models Humanized Immune-Checkpoint Mice Product Catalog Number B-hXCR1 mice 112815 B-h4-1BB, Tg(hLILRB1/hLILRB4) mice 112731 B-hCD3EDG/hCD19/hBCMA mice 113343   Humanized Cytokine Mice Product Catalog…

Read more
Biocytogen’s Antibody Partner Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024

On April 7, at AACR, our therapeutic antibody collaborator Syncromune delivered an oral presentation unveiling clinical data of its SYNC-T technology for the first time!…

Read more
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Beijing, China, March 25, 2024 --Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel…

Read more
Biocytogen Symposium 2024: New Targets, New Therapeutics

[embed]https://youtu.be/TPV_3gMmUvE?si=qgqV-_b_0euuhL5I[/embed] Thanks to all who joined us at the 2024 Biocytogen Symposium! Your participation made this event a tremendous success. Whether you joined us in person or…

Read more
Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Beijing, China, February 19, 2024 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences,…

Read more
Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Beijing, China – January 23, 2024 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of a new sub-brand, RenBiologicsTM, to…

Read more
Dr. Yuelei Shen Shared His Insights During Investment Reports/Newsweek Interview

Source: Investment Reports This interview, together with other interviews with the industry’s leading figures, will be published in the second edition of The New Era…

Read more
Back to top